Cellectar Biosciences's market cap is currently $14.47M. The company's EPS TTM is $-1.867; its P/E ratio is ―; Cellectar Biosciences is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is $-0.35. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -192.38K	$ -238.87K	$ -227.64K	$ -207.93K	$ -189.36K
Operating Income	$ -38.96M	$ -28.81M	$ -24.13M	$ -15.29M	$ -14.18M
EBITDA	$ -38.77M	$ -28.67M	$ -23.98M	$ -15.15M	$ -13.90M
Net Income	$ -37.98M	$ -28.60M	$ -23.97M	$ -14.76M	$ -13.87M
Balance Sheet
Cash & Short-Term Investments	$ 9.56M	$ 19.87M	$ 35.70M	$ 57.17M	$ 10.61M
Total Assets	$ 12.08M	$ 21.59M	$ 37.20M	$ 58.66M	$ 12.25M
Total Debt	$ 552.98K	$ 603.83K	$ 301.74K	$ 421.64K	$ 527.53K
Net Debt	$ -9.01M	$ -19.26M	$ -35.40M	$ -56.74M	$ -10.09M
Total Liabilities	$ 25.85M	$ 6.08M	$ 4.16M	$ 3.86M	$ 3.19M
Stockholders' Equity	$ -15.16M	$ 15.51M	$ 33.05M	$ 54.79M	$ 9.06M
Cash Flow
Free Cash Flow	$ -33.24M	$ -25.45M	$ -22.71M	$ -14.00M	$ -11.72M
Operating Cash Flow	$ -32.38M	$ -25.22M	$ -22.57M	$ -13.93M	$ -11.69M
Investing Cash Flow	$ -864.04K	$ -225.97K	$ -141.36K	$ -62.35K	$ -24.54K
Financing Cash Flow	$ 22.94M	$ 9.61M	$ 1.25M	$ 60.55M	$ 9.02M

Currency in USD

Cellectar Biosciences Earnings and Revenue History

Income Statement >

Cellectar Biosciences Debt to Assets

Balance Sheet >

Cellectar Biosciences Cash Flow

Cash Flow >

Cellectar Biosciences Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing